Chlorhexidine gluconate at 0.12% — Competitive Intelligence Brief

Chlorhexidine gluconate at 0.12% (Chlorhexidine gluconate at 0.12%) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimicrobial agent / Antiseptic. Area: Infectious Disease / Oral Health.

phase 3 Antimicrobial agent / Antiseptic Bacterial cell membrane Infectious Disease / Oral Health Small molecule

Target snapshot

Chlorhexidine gluconate at 0.12% (Chlorhexidine gluconate at 0.12%) — Universidad de Guanajuato. Chlorhexidine gluconate is a broad-spectrum antimicrobial agent that disrupts bacterial cell membranes and denatures proteins, leading to rapid bactericidal and bacteriostatic effects.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Chlorhexidine gluconate at 0.12% TARGET	Chlorhexidine gluconate at 0.12%	Universidad de Guanajuato	phase 3	Antimicrobial agent / Antiseptic	Bacterial cell membrane
Silvadene	Silver Sulfadiazine	Pfizer	marketed	sulfonamide antimicrobial	bacterial cell membrane and cell wall	1973-01-01
Ceftazidime-avibactam + Colistin/Polymyxin B	Ceftazidime-avibactam + Colistin/Polymyxin B	National University of Singapore	marketed	Beta-lactam/beta-lactamase inhibitor + polymyxin antibiotic combination	Bacterial peptidoglycan cross-linking enzymes (PBPs); beta-lactamases; bacterial cell membrane lipopolysaccharide and phospholipids
Chlorhexidine 0.2% Mouthrinse	Chlorhexidine 0.2% Mouthrinse	University of Oslo	marketed	Antimicrobial agent / Antiseptic	Bacterial cell membrane and proteins
A (Chloraprep)	A (Chloraprep)	Instituto de Investigacion Sanitaria La Fe	marketed	Topical antiseptic	Bacterial cell membrane and proteins
adapalene/benzoyl peroxide	adapalene/benzoyl peroxide	Galderma R&D	marketed	Retinoid + peroxide combination	Retinoic acid receptors (adapalene); bacterial cell membrane and proteins (benzoyl peroxide)
CHG antiseptic body cleanser	CHG antiseptic body cleanser	Baycrest	marketed	Antimicrobial antiseptic	Bacterial cell membrane

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimicrobial agent / Antiseptic class)

1. Universidad de Guanajuato · 2 drugs in this class
2. University of Oslo · 2 drugs in this class
3. Johns Hopkins University · 1 drug in this class
4. The Cooper Health System · 1 drug in this class
5. Universidade Federal do Ceara · 1 drug in this class
6. University of Milan · 1 drug in this class
7. University of Pavia · 1 drug in this class
8. University of Pennsylvania · 1 drug in this class
9. University of Santiago de Compostela · 1 drug in this class
10. HaEmek Medical Center, Israel · 1 drug in this class